Analysts Issue Forecasts for CADL FY2026 Earnings

Key Points

• Brookline Capital Markets forecast FY2026 EPS of a $1.28 loss for Candel Therapeutics, slightly better than the $1.30-loss consensus estimate.
• Analyst sentiment remains generally positive, with eight Buy ratings, two Holds and one Sell; the stock carries a “Moderate Buy” consensus and an average price target of $19.29.
• Candel reported a quarterly loss of $0.52 per share, missing expectations by $0.28, while shares recently opened at $12.35 after trading between $4.35 and $13.82 over the past year.

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Investment analysts at Brookline Capital Markets issued their FY2026 EPS estimates for shares of Candel Therapeutics in a research note issued on Wednesday, August 12th. Brookline Capital Markets analyst K. Dolliver forecasts that the company will earn ($1.28) per share for the year. The consensus estimate for Candel Therapeutics' current full-year earnings is ($1.30) per share.

Several other research firms have also issued reports on CADL. HC Wainwright reiterated a "buy" rating and set a $23.00 price objective on shares of Candel Therapeutics in a research note on Thursday, August 13th. Wall Street Zen cut Candel Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. Bank of America boosted their target price on shares of Candel Therapeutics from $9.00 to $12.00 and gave the stock a "neutral" rating in a research note on Friday, August 14th. Zacks Research upgraded shares of Candel Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Friday, May 15th. Finally, Stifel Nicolaus initiated coverage on Candel Therapeutics in a research report on Monday, July 13th. They set a "buy" rating and a $22.00 target price for the company. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $19.29.

Candel Therapeutics Price Performance

Shares of Candel Therapeutics stock opened at $12.35 on Friday. The firm has a market cap of $945.02 million, a P/E ratio of -8.76 and a beta of -0.51. The company has a debt-to-equity ratio of 0.38, a quick ratio of 16.09 and a current ratio of 16.09. Candel Therapeutics has a twelve month low of $4.35 and a twelve month high of $13.82. The firm's 50-day simple moving average is $10.01 and its 200-day simple moving average is $7.60.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.28).

Hedge Funds Weigh In On Candel Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CADL. Janus Henderson Group PLC acquired a new stake in Candel Therapeutics in the 1st quarter valued at approximately $845,000. Halter Ferguson Financial Inc. boosted its holdings in Candel Therapeutics by 20.9% during the first quarter. Halter Ferguson Financial Inc. now owns 904,051 shares of the company's stock worth $4,430,000 after purchasing an additional 155,996 shares during the last quarter. Walleye Capital LLC bought a new position in Candel Therapeutics in the second quarter valued at $419,000. Renaissance Technologies LLC acquired a new stake in Candel Therapeutics in the 1st quarter valued at $63,000. Finally, AlphaCentric Advisors LLC bought a new stake in Candel Therapeutics during the 1st quarter worth about $178,000. 13.93% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Francesca Barone sold 23,447 shares of the firm's stock in a transaction on Monday, June 29th. The stock was sold at an average price of $10.06, for a total transaction of $235,876.82. Following the sale, the insider owned 77,362 shares of the company's stock, valued at approximately $778,261.72. This trade represents a 23.26% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CTO Seshu Tyagarajan sold 7,000 shares of the firm's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $12.00, for a total value of $84,000.00. Following the sale, the chief technology officer directly owned 76,865 shares in the company, valued at approximately $922,380. This represents a 8.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 37,447 shares of company stock valued at $390,017. 14.30% of the stock is owned by corporate insiders.

About Candel Therapeutics

Candel Therapeutics NASDAQ: CADL is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company's lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel's pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source